Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Dihexa cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established Dihexa cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Dihexa combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Dihexa cycle length?
No. We found no human studies that report a treatment duration for Dihexa.
What is the longest human study of Dihexa?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Dihexa dosing reference Full research page

References

  1. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents (Expression of Concern: J Pharmacol Exp Ther 2021;378:313) Journal of Pharmacology and Experimental Therapeutics. 2013
  2. RETRACTED: The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system Journal of Pharmacology and Experimental Therapeutics. 2014
  3. Retraction notice to "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System" [J Pharmacol Exp Ther 351 (2014) 390-402] Journal of Pharmacology and Experimental Therapeutics. 2025
  4. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure Frontiers in Cellular Neuroscience. 2015
  5. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease Journal of Alzheimer's Disease. 2015
  6. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases Progress in Neurobiology. 2015
  7. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies Neuroscience & Biobehavioral Reviews. 2018
  8. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway Brain Sciences. 2021
  9. Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies Annals of Medicine and Surgery. 2021
  10. Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats Journal of Huntington's Disease. 2024
  11. Dihexa (CID 129010512): compound summary, synonyms (PNB-0408, ATH-1001) and computed properties PubChem. 2026
  12. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions JAAOS Global Research & Reviews. 2026
  13. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  14. ClinicalTrials.gov search for Dihexa, PNB-0408 and ATH-1001 (no registered studies identified) ClinicalTrials.gov. 2026
  15. World Anti-Doping Code International Standard Prohibited List 2026 WADA. 2026